The search for a magic bullet to kill only cancer cells has been on for years.
© Getty Images
New candidate cancer drug does damage only in tumours.
A new drug turns lethal only when it reaches cancer cells. In healthy cells it is harmless. Though not yet shown to work in humans, it is a step towards a magic bullet to knock out tumour cells selectively, with minimal side effects.
The drug works in mice implanted with human tumours, say chemists Lutz Tietze and colleagues at the University of Gottingen in Germany. Before being treated with the drug, the mice are given an enzyme to activate it that sticks only to the human tumour cells, ignoring healthy mouse cells. So the drug is safe until the enzyme activates it in the tumour. Then it destroys the cancerous cells1.
Most existing chemotherapy is toxic to normal cells as well as cancerous ones. This causes severe side effects, such as a depressed immune system. Cancer researchers long for a magic bullet: a drug that works only where it is needed.
The warhead of the Gottingen antitumour molecule is a ring of three carbon atoms. This ring is highly strained and apt to burst open. Open, it is a reactive molecule that wreaks havoc among the nucleic acid molecules essential for normal cell function. The chemists copied this trick from a highly toxic antibiotic produced by a fungus.
So that their molecular bomb does not detonate everywhere in the body, the team have made a ’prodrug’. This is like the natural antibiotic but without the strained ring and with a sugar safety-catch. Once the sugar is clipped off, the molecule rearranges itself into a three-atom ring, and proceeds to do its toxic business.
Tietze’s team uses an enzyme to cut away the sugar safety-catch. An antibody on the enzyme acts as a tumour-specific hook. Such antibodies linked to toxic or radioactive molecules have long been explored for making magic-bullet drugs; none has yet found clinical use.
The advantage of this enzyme-activated approach, originally developed in the 1980s, is that the drug isn’t even activated until it reaches the target site. The selectivity of the damage still depends on antibody’s ability to hook onto the right cells, and on the absence of other enzymes in the body that also activate the prodrug.
Whether the idea will work cleanly enough in humans remains to be seen.
PHILIP BALL | © Nature News Service
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy